skip to the content

Tarceva first-line in EGFR Mut+ NSCLC

Tarceva is indicated for the first-line treatment of patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations1


Tarceva in the post-platinum setting

  • Tarceva is indicated as monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC with stable disease after 4 cycles of standard platinum-based first-line chemotherapy1
 
  • Tarceva is also indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen1




Role for Tarceva in advanced NSCLC treatment

 

Reference

  1. Tarceva® (erlotinib) Summary of Product Characteristics, F. Hoffmann-La Roche Ltd., 2011.

SmPC

The EU product label for Tarceva is available in different languages.

Mechanism of action

Mechanism of Action

Click to access and download the new Tarceva mechanism of action video.

New indication for Tarceva

Tarceva is now approved for first-line therapy of EGFR Mut+ NSCLC.

Tarceva.com

This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit http://www.tarceva.com/.